Pluristem Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2018 Annual Meeting of Stockholders held by Pluristem Therapeutics Inc. on May 31, 2018. The company is incorporated in Nevada with principal executive offices in Haifa, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The stockholders approved two proposals at the Annual Meeting:
- Proposal 1: Election of Directors - All nine nominees were elected. The total votes cast included significant "For" votes for each director, with Broker Non-Votes totaling 25,552,412 for each nominee.
- Proposal 2: Ratification of Auditors - The selection of Kost Forer Gabbay & Kasierer (a member of Ernst & Young Global) as the independent registered public accounting firm for the fiscal year ending June 30, 2018, was ratified with 52,041,038 votes "For" and 1,158,889 votes "Against".
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that all nine director nominees were successfully elected.
- Verification of the auditor ratification for the fiscal year ending June 30, 2018.
- Review of the specific vote counts for directors to assess shareholder sentiment, noting the high volume of broker non-votes.